Breaking News

ACM Global Expands Asia-Pac Footprint

By Kristin Brooks | January 23, 2014

Acquires Phoenix Pharma Central Services

ACM Global Central Laboratory has acquired Phoenix Pharma Central Services Pte. Ltd. (Phoenix PCS), a central lab services provider with facilities in Singapore and Shanghai, China. The acquisition allows ACM Global to increase operations and efficiencies for clients conducting clinical studies in the Asia Pacific region. Financial terms were not disclosed.
 
With the acquisition, ACM Global gains an established lab in Singapore that offers extensive clinical trials experience and knowledge of regional regulatory requirements, country specific logistics, and familiarity with customs and local languages, as well as Phoenix PCS’ new lab facility in Shanghai, China.
 
“This acquisition is a major milestone in our organization’s growth and represents a significant investment and commitment to the region,” said Angela J. Panzarella, president of ACM Medical Laboratory, Inc., the parent company of ACM Global Central Laboratory. “We have a long and successful history of working with partner labs in Asia, but as part of our commitment to providing robust global capabilities, operational and scientific expertise and unsurpassed service to our customers, it was important for us to establish a network of ACM Global-owned and operated labs in the Asia-Pacific region, which we see as an increasingly important region for clinical research. We are extremely pleased to be gaining the expert staff, state-of-the-art facilities and local knowledge that Phoenix PCS provides.”
 
“We are excited to be joining the ACM Global team,” Dr. Lee said. “My staff and I have worked very hard to create a central lab that values high quality services above all else and feel our experience, knowledge, and focus on client service fit very well with ACM and its core values. With the resources and opportunities available through ACM, we can further enhance our core services and provide even greater value to our clients, partners, and suppliers. We are looking forward to being a part of ACM’s ongoing growth and success, both in the Asia-Pacific region and globally.”

Related Packaging:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research